La Quinta Mobile App Cross Platform Development
BASIC
- Around 5 Screens.
- Around 5 Integrations
- Only simple validations on device
- No-obligation inquiry.
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
STANDARD
- Around 10 Screens
- Around 10 Integrations
- Simple business logic for Validations / Calculations / Chart Data etc.
- Some local storage of data
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
- 1 Project Manager (shared)
- 1 Team Lead (shared)
PREMIUM
- Around 20 Screens
- Around 20 Integrations
- Complex business logic like Interactive Charts, Animations, Validations, Conditions etc.
- Complete local storage of data used by App
- We will create suggestions on monthly basis for improvement for you.
Cross-Platform App Development Services & Solutions in La Quinta
We take your groundwork and create a market-ready app based on your needs while you focus on product and company growth.
Flutter is the fastest-growing cross-platform development framework. It was introduced in 2017 by Google and managed to gain great popularity among cross-platform programmers.
La Quinta News
French antitrust watchdog dismisses complaint filed against Microsoft
The French antitrust watchdog on Thursday dismissed a complaint filed against Microsoft by local search engine Qwant ...
Of OFWs, 380 million trees, and a national-scale agroforestry program
So as we roll out a national-scale agroforestry program, it’s not just about planting 380 million trees. It’s about planting 380 million chances. 380 million possibilities. 380 million reasons for ...
World’s Largest ADHD Treatment Review Reveals What Really Works
A new online tool is designed to help families and clinicians make informed treatment decisions. The most extensive assessment so far of available ADHD treatments reports that medication for both ...
Regulatory, patent barriers may hinder global access to new HIV prevention drug: activists
Activists urge India to waive clinical trial requirements for lenacapavir, as patent barriers threaten access to the vital HIV prevention drug.